{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:02:11Z","timestamp":1787241731798,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jchromb.2024.124229","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:37:33Z","timestamp":1719977853000},"page":"124229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers"],"prefix":"10.1016","volume":"1243","author":[{"given":"Srijita","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om Prakash","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124229_b0005","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic myeloid leukemia: mechanisms of resistance and treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.jchromb.2024.124229_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jchromb.2024.124229_b0015","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jchromb.2024.124229_b0020","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jchromb.2024.124229_b0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.jchromb.2024.124229_b0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2280.2280","article-title":"Nilotinib and dasatinib produce synergistic growth-inhibitory effects in imatinib-resistant CML cells, including subclones bearing the multi-resistant BCR\/ABL mutant T315I","volume":"116","author":"Gleixner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jchromb.2024.124229_b0035","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)\u2013based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jchromb.2024.124229_b0040","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2009.242","article-title":"Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jchromb.2024.124229_b0045","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.2147\/DDDT.S85050","article-title":"Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations","volume":"10","author":"Keskin","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jchromb.2024.124229_b0050","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/11207580-000000000-00000","article-title":"Dasatinib","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jchromb.2024.124229_b0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jchromb.2024.124229_b0060","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jchromb.2024.124229_b0065","unstructured":"National Center for Biotechnology Information, 2024, PubChem Compound Summary for CID 644241, Nilotinib. Retrieved January, (n.d.). (accessed on 31st January 2024)."},{"key":"10.1016\/j.jchromb.2024.124229_b0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2015.12.003","article-title":"Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and\/or renal dysfunction","volume":"16","author":"Sasaki","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.jchromb.2024.124229_b0075","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1021\/acs.oprd.9b00238","article-title":"Development and optimization of liquid chromatography analytical methods by using AQbD principles: overview and recent advances","volume":"23","author":"Tome","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jchromb.2024.124229_b0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2116\/analsci.27.493","article-title":"Rapid determination of quinoline and 2-hydroxyquinoline in quinoline biodegradation process by tri-wavelength UV\/Vis spectroscopy","volume":"27","author":"Deng","year":"2011","journal-title":"Anal. Sci."},{"key":"10.1016\/j.jchromb.2024.124229_b0085","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1039\/c3ay42330a","article-title":"Design and study of a HPLC method for the simultaneous estimation of two anti-diabetic drugs using a statistical approach","volume":"6","author":"Saladi","year":"2014","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jchromb.2024.124229_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106491","article-title":"Development and validation of RP-HPLC method for quantification of repaglinide in mPEG-PCL polymeric nanoparticles: QbD-driven optimization, force degradation study, and assessment of in vitro release mathematic modeling","volume":"168","author":"Wadhwa","year":"2021","journal-title":"Microchem. J."},{"key":"10.1016\/j.jchromb.2024.124229_b0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26774-y","article-title":"Factorial design-assisted reverse phase HPLC\u2013UV approach for the concurrent estimation of cetirizine and azelastine in aqueous humor","volume":"12","author":"Abd-AlGhafar","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jchromb.2024.124229_b0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.microc.2019.03.039","volume":"147","author":"EL-Shorbagy","year":"2019","journal-title":"Microchem. J."},{"key":"10.1016\/j.jchromb.2024.124229_b0105","unstructured":"International Conference on Harmonization. ICH Q2 (R1): validation of analytical procedures: text and methodology, ICH Secretariat, Geneva, 2005, (n.d.) (accessed on 31st January 2024)."},{"key":"10.1016\/j.jchromb.2024.124229_b0110","doi-asserted-by":"crossref","first-page":"21618","DOI":"10.1021\/acsomega.3c00956","article-title":"QbD-engineered development and validation of a RP-HPLC method for simultaneous estimation of rutin and ciprofloxacin HCl in bilosomal nanoformulation","volume":"8","author":"Shamim","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.jchromb.2024.124229_b0115","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6143061","article-title":"Development and validation of an HPLC method for simultaneous assay of potassium guaiacolsulfonate and sodium benzoate in pediatric oral powder","volume":"2019","author":"Le","year":"2019","journal-title":"J. Anal. Methods Chem."},{"key":"10.1016\/j.jchromb.2024.124229_b0120","article-title":"Experimental design approach, screening and optimization of system variables, analytical method development of flurbiprofen in nanoparticles and stability-indicating methods for high-pressure liquid chromatography","volume":"8","author":"Mandpe","year":"2022","journal-title":"Fut. J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2024.124229_b0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs\u2014a review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jchromb.2024.124229_b0130","doi-asserted-by":"crossref","unstructured":"R.-J. Ju, X.-T. Li, Preparation and Characterization of Drug Liposomes by Ammonium Sulfate Gradient, 2021, pp. 59\u201377, doi: 10.1007\/978-3-662-49320-5_4.","DOI":"10.1007\/978-3-662-49320-5_4"},{"key":"10.1016\/j.jchromb.2024.124229_b0135","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.2147\/IJN.S309804","article-title":"Dual-ligand-modified liposomes co-loaded with anti-angiogenic and chemotherapeutic drugs for inhibiting tumor angiogenesis and metastasis","volume":"16","author":"Wang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jchromb.2024.124229_b0140","article-title":"Dual drug-loaded nanoliposomes encapsulating curcumin and 5-fluorouracil with advanced medicinal applications: self-monitoring and antitumor therapy","volume":"28","author":"Liu","year":"2023","journal-title":"Molecules"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224002381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224002381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:30:51Z","timestamp":1728347451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224002381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"alternative-id":["S1570023224002381"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124229","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124229"}}